Where is the live CopyMark page for USPTO serial 99698608?

The live record is at https://getcopymark.com/trademark/99698608. Use https://getcopymark.com/trademark/{serialNumber} for any 8-digit USPTO serial.

Who owns ACTINIUM PHARMACEUTICALS?

According to the public USPTO record for serial number 99698608, the listed owner(s) include: Actinium Pharmaceuticals, Inc..

What is USPTO serial number 99698608?

Serial number 99698608 is the USPTO application identifier for the mark ACTINIUM PHARMACEUTICALS. It is used to track examination, publication, and registration of this trademark.

What is the current status of ACTINIUM PHARMACEUTICALS?

ACTINIUM PHARMACEUTICALS (99698608) currently shows USPTO status code 681 on the public record. This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Which trademark classes cover ACTINIUM PHARMACEUTICALS?

The public record lists International Classes: 001, 005, 042. Each class corresponds to categories of goods or services identified in the application or registration.

Trademark: ACTINIUM PHARMACEUTICALS Serial# 99698608 | status 681; last event NONP | Trademark Info & Attorney Guidance

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with ACTINIUM PHARMACEUTICALS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner

Monitor this mark, or talk with CopyMark about this registration.

Trademark Monitoring

(312) 319-4460

Not the owner?

File a new U.S. trademark application, or speak with our attorneys.

Start a new application

(312) 319-4460

Owner

Actinium Pharmaceuticals, Inc.
New York, NY, US
Other trademarks owned by Actinium Pharmaceuticals, Inc.

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Michael E. Dukes

Michael E. Dukes Dentons Cohen & Grigsby, P.C.625 Liberty Ave.Pittsburgh, PA 15222United States

Goods and services

Class	Description	Status	First use
001	Radiopharmaceutical antibody preparations for scientific purposes	ACTIVE	—
005	Medicinal preparations for use in oncology; pharmaceutical preparations and substances for the treatment of oncological related diseases and disorders; radiopharmaceutical antibody preparations for medical purposes	ACTIVE	—
042	Scientific research and development; Pharmaceutical research and development; Research and development of antibodies; Research and development of medicines; Research and development of new products; Research and development of conjugated antibodies; Research and development in the field of pharmaceuticals; Research and development of advanced learning technologies and teaching methods; Research and development of pharmaceuticals for the treatment of age-related diseases and cancer	ACTIVE	—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Date	Code	Event	What it means
Nov 11, 2026	NONP	NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED	—
Oct 22, 2026	CNSA	APPROVED FOR PUB - PRINCIPAL REGISTER	—
Oct 21, 2026	TEME	TEAS/EMAIL CORRESPONDENCE ENTERED	—
Oct 21, 2026	CRFA	CORRESPONDENCE RECEIVED IN LAW OFFICE	—
Oct 21, 2026	TROA	TEAS RESPONSE TO OFFICE ACTION RECEIVED	This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 21, 2026	TEME	TEAS/EMAIL CORRESPONDENCE ENTERED	—
Oct 21, 2026	CRFA	CORRESPONDENCE RECEIVED IN LAW OFFICE	—
Oct 21, 2026	TROA	TEAS RESPONSE TO OFFICE ACTION RECEIVED	This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jul 21, 2026	GNRN	NOTIFICATION OF NON-FINAL ACTION E-MAILED	A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 21, 2026	GNRT	NON-FINAL ACTION E-MAILED	A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 21, 2026	CNRT	NON-FINAL ACTION WRITTEN	A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 14, 2026	DOCK	ASSIGNED TO EXAMINER	—
Jul 14, 2026	MDSC	NOTICE OF DESIGN SEARCH CODE E-MAILED	—
Jul 13, 2026	NWOS	NEW APPLICATION OFFICE SUPPLIED DATA ENTERED	—
Mar 12, 2026	MAFR	APPLICATION FILING RECEIPT MAILED	—
Mar 12, 2026	NWAP	NEW APPLICATION ENTERED	—

ACTINIUM PHARMACEUTICALS